Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma
Radiation Oncology Journal
;
: 163-169, 2014.
Article
in English
| WPRIM
| ID: wpr-209402
ABSTRACT
PURPOSE:
To report the results of stereotactic body radiotherapy (SBRT) for unresectable primary or recurrent cholangiocarcinoma. MATERIALS ANDMETHODS:
From January 2005 through August 2013, 58 patients with unresectable primary (n = 28) or recurrent (n = 30) cholangiocarcinoma treated by SBRT were retrospectively analyzed. The median prescribed dose was 45 Gy in 3 fractions (range, 15 to 60 Gy in 1-5 fractions). Patients were treated by SBRT only (n = 53) or EBRT + SBRT boost (n = 5). The median tumor volume was 40 mL (range, 5 to 1,287 mL).RESULTS:
The median follow-up duration was 10 months (range, 1 to 97 months). The 1-year, 2-year overall survival rates, and median survival were 45%, 20%, and 10 months, respectively. The median survival for primary group and recurrent group were 5 and 13 months, respectively. Local control rate at 1-year and 2-year were 85% and 72%, respectively. Disease progression-free survival rates at 1-year and 2-year were 26% and 23%, respectively. In univariate analysis, ECOG performance score (0-1 vs. 2-3), treatment volume ( or =50 mL), and pre-SBRT CEA level ( or =5 ng/mL) were significant in overall survival rate. In multivariate analysis, ECOG score (p = 0.037) and tumor volume (p = 0.030) were statistically significant. In the recurrent tumor group, patients with >12 months interval from surgery to recurrence showed statistically significant higher overall survival rate than those with or =grade 3 complications.CONCLUSION:
SBRT can be considered as an effective local modality for unresectable primary or recurrent cholangiocarcinoma.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recurrence
/
Multivariate Analysis
/
Survival Rate
/
Retrospective Studies
/
Follow-Up Studies
/
Radiosurgery
/
Cholangiocarcinoma
/
Disease-Free Survival
/
Tumor Burden
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Radiation Oncology Journal
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS